Check-Cap Ltd. (CHEK)
USD 0.67
(-0.95%)
USD 0.67
(-0.95%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -19.28 Million USD | 3.73% |
| 2022 | -20.03 Million USD | -15.66% |
| 2021 | -17.32 Million USD | -24.33% |
| 2020 | -13.93 Million USD | 0.97% |
| 2019 | -14.06 Million USD | -27.17% |
| 2018 | -11.06 Million USD | -10.62% |
| 2017 | -10 Million USD | -10.36% |
| 2016 | -9.06 Million USD | 27.29% |
| 2015 | -12.46 Million USD | -159.11% |
| 2014 | -4.81 Million USD | -28.54% |
| 2013 | -3.74 Million USD | 4.25% |
| 2012 | -3.9 Million USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 Q4 | -4.08 Million USD | -39.66% |
| 2023 Q2 | -7.42 Million USD | -53.13% |
| 2023 FY | -17.86 Million USD | 10.85% |
| 2023 Q1 | -4.85 Million USD | -15.07% |
| 2023 Q3 | -2.92 Million USD | 60.62% |
| 2022 FY | -20.03 Million USD | -15.66% |
| 2022 Q3 | -5.04 Million USD | -3.21% |
| 2022 Q4 | -4.21 Million USD | 16.45% |
| 2022 Q2 | -4.88 Million USD | 16.94% |
| 2022 Q1 | -5.88 Million USD | -5.5% |
| 2021 Q3 | -4.26 Million USD | -8.67% |
| 2021 Q2 | -3.92 Million USD | -10.29% |
| 2021 FY | -17.32 Million USD | -24.33% |
| 2021 Q4 | -5.57 Million USD | -30.85% |
| 2021 Q1 | -3.55 Million USD | 9.56% |
| 2020 Q4 | -3.93 Million USD | -208.32% |
| 2020 Q1 | -3.41 Million USD | 11.13% |
| 2020 Q2 | -2.94 Million USD | 13.75% |
| 2020 Q3 | 3.63 Million USD | 223.13% |
| 2020 FY | -13.93 Million USD | 0.97% |
| 2019 Q2 | -3.49 Million USD | -10.43% |
| 2019 FY | -14.06 Million USD | -27.17% |
| 2019 Q3 | -3.56 Million USD | -2.0% |
| 2019 Q1 | -3.16 Million USD | 8.79% |
| 2019 Q4 | -3.84 Million USD | -7.94% |
| 2018 Q3 | -2.8 Million USD | -4.28% |
| 2018 FY | -11.06 Million USD | -10.62% |
| 2018 Q4 | -3.46 Million USD | -23.8% |
| 2018 Q2 | -2.68 Million USD | -27.65% |
| 2018 Q1 | -2.1 Million USD | -2.28% |
| 2017 Q2 | -2.8 Million USD | -1.59% |
| 2017 Q3 | -7.94 Million USD | -182.97% |
| 2017 Q4 | -2.05 Million USD | 74.09% |
| 2017 FY | -10 Million USD | -10.36% |
| 2017 Q1 | -2.76 Million USD | -13.52% |
| 2016 Q3 | -1.75 Million USD | 11.19% |
| 2016 FY | -9.06 Million USD | 27.29% |
| 2016 Q1 | -2.9 Million USD | 5.01% |
| 2016 Q2 | -1.97 Million USD | 31.9% |
| 2016 Q4 | -2.43 Million USD | -38.77% |
| 2015 Q2 | -2.56 Million USD | 33.56% |
| 2015 Q1 | -3.86 Million USD | -124.06% |
| 2015 Q4 | -3.05 Million USD | -1.36% |
| 2015 Q3 | -3.01 Million USD | -17.29% |
| 2015 FY | -12.46 Million USD | -159.11% |
| 2014 Q3 | -881 Thousand USD | 20.77% |
| 2014 Q1 | -1.09 Million USD | -4.6% |
| 2014 Q2 | -1.11 Million USD | -1.83% |
| 2014 Q4 | -1.72 Million USD | -95.8% |
| 2014 FY | -4.81 Million USD | -28.54% |
| 2013 Q2 | -953 Thousand USD | -1.17% |
| 2013 Q4 | -1.04 Million USD | 0.0% |
| 2013 FY | -3.74 Million USD | 4.25% |
| 2013 Q1 | -942 Thousand USD | 0.0% |
| 2013 Q3 | -1.04 Million USD | -9.55% |
| 2012 FY | -3.9 Million USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Aclaris Therapeutics, Inc. | -97.35 Million USD | 80.189% |
| Applied DNA Sciences, Inc. | -10.95 Million USD | -76.084% |
| Aspira Women's Health Inc. | -18.85 Million USD | -2.307% |
| Biodesix, Inc. | -41.34 Million USD | 53.348% |
| BioNexus Gene Lab Corp. | -2.59 Million USD | -643.642% |
| bioAffinity Technologies, Inc. | -7.97 Million USD | -141.897% |
| bioAffinity Technologies, Inc. | -7.97 Million USD | -141.897% |
| Bionano Genomics, Inc. | -215.24 Million USD | 91.04% |
| CareDx, Inc | -101.9 Million USD | 81.073% |
| Castle Biosciences, Inc. | -67.97 Million USD | 71.627% |
| DarioHealth Corp. | -56.18 Million USD | 65.675% |
| Exact Sciences Corporation | -215.01 Million USD | 91.03% |
| Fulgent Genetics, Inc. | -72.69 Million USD | 73.469% |
| Guardant Health, Inc. | -564.72 Million USD | 96.585% |
| ICON Public Limited Company | 956.15 Million USD | 102.017% |
| IDEXX Laboratories, Inc. | 1.09 Billion USD | 101.758% |
| Illumina, Inc. | -1.06 Billion USD | 98.196% |
| Intelligent Bio Solutions Inc. | -10.28 Million USD | -87.559% |
| iSpecimen Inc. | -11.16 Million USD | -72.678% |
| Standard BioTools Inc. | -76.6 Million USD | 74.821% |
| MDxHealth SA | -27.32 Million USD | 29.421% |
| 23andMe Holding Co. | -321.35 Million USD | 93.998% |
| Medpace Holdings, Inc. | 336.82 Million USD | 105.726% |
| Myriad Genetics, Inc. | -123.7 Million USD | 84.408% |
| Mainz Biomed B.V. | -26.64 Million USD | 27.614% |
| ENDRA Life Sciences Inc. | -10.52 Million USD | -83.324% |
| NeoGenomics, Inc. | -107.73 Million USD | 82.098% |
| Neogen Corporation | 58.66 Million USD | 132.878% |
| Inotiv, Inc. | -81.46 Million USD | 76.323% |
| Natera, Inc. | -446.24 Million USD | 95.678% |
| OpGen, Inc. | -15.68 Million USD | -22.937% |
| OPKO Health, Inc. | -157.02 Million USD | 87.717% |
| Psychemedics Corporation | -2.92 Million USD | -560.288% |
| Prenetics Global Limited | -52.51 Million USD | 63.272% |
| Prenetics Global Limited | -52.51 Million USD | 63.272% |
| Precipio, Inc. | -7.62 Million USD | -153.11% |
| Personalis, Inc. | -109.93 Million USD | 82.456% |
| RadNet, Inc. | 98.69 Million USD | 119.542% |
| Sera Prognostics, Inc. | -39.82 Million USD | 51.566% |
| Sotera Health Company | 276.69 Million USD | 106.971% |
| Neuronetics, Inc. | -30.55 Million USD | 36.876% |
| Star Equity Holdings, Inc. | -4.34 Million USD | -343.787% |
| Star Equity Holdings, Inc. | -4.34 Million USD | -343.787% |
| Trinity Biotech plc | -27.04 Million USD | 28.686% |
| T2 Biosystems, Inc. | -49.66 Million USD | 61.165% |
| Twist Bioscience Corporation | -220.83 Million USD | 91.266% |
| Exagen Inc. | -22.83 Million USD | 15.545% |